Affimed (NASDAQ:AFMD) Receives Average Rating of “Buy” from Analysts

Shares of Affimed (NASDAQ:AFMD) have been given an average rating of “Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $41.67.

Several research firms have commented on AFMD. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. Laidlaw lifted their price objective on Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Wells Fargo & Company dropped their target price on Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, April 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Thursday, June 13th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AFMD. Vestal Point Capital LP acquired a new stake in Affimed during the fourth quarter worth about $341,000. abrdn plc acquired a new stake in Affimed during the 4th quarter worth approximately $130,000. BNP Paribas Financial Markets raised its holdings in Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after buying an additional 163,162 shares during the period. Finally, EWA LLC acquired a new position in Affimed during the fourth quarter valued at approximately $89,000. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Price Performance

Shares of NASDAQ:AFMD opened at $5.12 on Friday. The stock’s fifty day simple moving average is $5.49 and its 200-day simple moving average is $5.59. Affimed has a 52-week low of $2.23 and a 52-week high of $8.95. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.06 and a current ratio of 3.06.

Affimed (NASDAQ:AFMD) last released its quarterly earnings results on Wednesday, June 12th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.73) by $0.35. The company had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $1.76 million. Affimed had a negative net margin of 2,361.94% and a negative return on equity of 135.81%. On average, research analysts predict that Affimed will post -3.6 EPS for the current year.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.